Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis

Semaje Testamark, Allison Verbyla, Myra Robinson, Peter M. Voorhees, Manisha Bhutani

Blood (2023) 142 (Supplement 1): 1977.

https://doi.org/10.1182/blood-2023-175032

Published: 2023

Journal Articles

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Hamid Ehsan, Myra Robinson, Patrick Meadors, Rushil Patel, Shanice Borden, Peter M. Voorhees, Delcan Walsh, Barry Paul, Manisha Bhutani, Cindy Varga, Shebli Atrash

Blood (2023) 142 (Supplement 1): 7416.

https://doi.org/10.1182/blood-2023-178114

Published: 2023

Journal Articles

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Manisha Bhutani, Myra Robinson, Shebli Atrash, Barry Paul, Mauricio Pineda-Roman, David Foureau, Cindy Varga, Reed Friend, Xhevahire Begic, Sarah Norek, Tiffany Drennan, Michelle B Anderson, James Symanowski, Peter M. Voorhees, Saad Z Usmani

Blood (2023) 142 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2023-174972

Published: 2023

Journal Articles

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Ifeyinwa Osunkwo, Myra Robinson, Anya Griffin, Azizi Coleman, Sharvil Desai, Padmaja Veeramreddy, Payal Desai, Charity Patterson, James Symanowski, Paulette Bryant, Jennifer Cornette, Wally R Smith, James R Eckman, Ramona Lawrence

Blood (2023) 142 (Supplement 1): 5048.

https://doi.org/10.1182/blood-2023-186835

Published: 2023

Journal Articles

Implementing a Structured Health Care Transition (HCT) Process for Sickle Cell Disease Using Quality Improvement: Results from the Sickle Cell Trevor Thompson Transition Project HCT Learning Collaborative

Ifeyinwa Osunkwo, Jennifer Cornette, Cheryl Courtlandt, Myra Robinson, Patience White, Margaret McManus, Laura Noonan, Payal Desai, Charity Patterson, James R. Eckman, Ramona Lawrence

Blood (2023) 142 (Supplement 1): 248.

https://doi.org/10.1182/blood-2023-187815

Published: 2023

Journal Articles

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Manisha Bhutani, Myra Robinson, Barry Paul, Shebli Atrash, Cindy Varga, Xhevahire Begic, David M Foureau, Mauricio Pineda-Roman, Brinda Koya, Sarah Norek, Sara A Sutton, Michelle B Anderson, Donna Acampora, James T Symanowski, Peter M. Voorhees, Saad Usmani

Blood (2022) 140 (Supplement 1): 4440–4441.

https://doi.org/10.1182/blood-2022-160204

Published: 2022

Journal Articles

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Srinivasa Reddy Sanikommu, Shebli Atrash, Myra Robinson, Nury M. Steuerwald, Kristen Cassetta, Hsih-Te Yang, Saad Usmani, Edward A. Copelan, Belinda R. Avalos, Lawrence J. Druhan

Blood (2022) 140 (Supplement 1): 11416–11417.

https://doi.org/10.1182/blood-2022-170887

Published: 2022

Journal Articles

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Blood (2022) 140 (Supplement 1): 4393–4395.

https://doi.org/10.1182/blood-2022-160071

Published: 2022

Journal Articles

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Manisha Bhutani, Myra Robinson, Shebli Atrash, David M Foureau, Katherine Rigby, Reed Friend, Barry Paul, James T Symanowski, Lawrence J Druhan, Sarah Norek, Mallory Tucker, Mauricio Pineda-Roman, Peter M. Voorhees, Saad Z. Usmani

Blood (2021) 138 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2021-148508

Published: 2021

Journal Articles

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Heather Cranford, CPhT, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136578

Published: 2020

Journal Articles

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Barry Paul, MDMS, Myra Robinson, MSPH, Kristen Cassetta, Daniel Slaughter, Jordan Robinson, Ami P Ndiaye, NP, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA, Shebli Atrash, MD

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-141637

Published: 2020

Journal Articles

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Shebli Atrash, MD, Myra Robinson, MSPH, Barry Paul, MDMS, Sarah Norek, BSN, RN, David M. Foureau, PhD, Carrie Ann Syfert, BSN, RN, Ami P Ndiaye, NP, James T Symanowski, PhD, Jordan Robinson, Manisha Bhutani, MD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141562

Published: 2020

Journal Articles

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Thomas G. Knight, MD, Melissa Aguiar, MSN, RN, Myra Robinson, MSPH, Allison Martin, PharmD, Tommy Chen, BS, Rupali Bose, MS, MBA, Jing Ai, MDPhD, Brittany K. Ragon, MD, Aleksander L. Chojecki, MD, Nilay A. Shah, MD, Srinivasa R. Sanikommu, MD, James Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-137222

Published: 2020

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Thomas G. Knight, MD, Myra Robinson, MS, Jing Ai, MD PhD, Brittany K Ragon, MD, Rhonda Davis, RN, BSN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Hailey Glover, RN, BSN, Jigar Trivedi, MSc, PharmD, Belinda R Avalos, MD, Jonathan M. Gerber, MD, James T Symanowski, PhD, Edward A Copelan, Michael R. Grunwald, MD

Blood (2019) 134 (Supplement_1): 2099.

https://doi.org/10.1182/blood-2019-128858

Published: 2019

Journal Articles

Patient Reported Financial Toxicity in Acute Leukemia

Thomas G. Knight, MD, Myra Robinson, MS, Michael R. Grunwald, MD, Lauren M. Bohannon, Erin Blackwell, RN, BSN, OCN, Jing Ai, MD, Brittany Ragon, MD, Rhonda Davis, BSN, RN, Cindy Shiflett, LPN, Erica Ruston, RN, BSN, Jigar Trivedi, MSc, PharmD, Justin Arnall, PharmD, CPP, BCOP, Belinda Rene Avalos, MD, James T Symanowski, PhD, Edward A. Copelan, MD, Jonathan M. Gerber, MD

Blood (2018) 132 (Supplement 1): 4796.

https://doi.org/10.1182/blood-2018-99-119163

Published: 2018

Journal Articles

Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients

David M. Foureau, PhD, Manisha Bhutani, MD, Myra Robinson, MS, Fei Guo, PhD, Duy Pham, Shelley Force Aldred, Ben Buelow, MD PhD, Katherine Rigby, Elise Tjaden, Marina Leonidas, Shebli Atrash, Ami P Ndiaye, NP, James Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MD

Blood (2018) 132 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2018-99-118881

Published: 2018

NARROW

Rural-Urban and Racial Trends in Survival of Patients with Multiple Myeloma: 1975-2019 Surveillance, Epidemiology, and End Results (SEER) Analysis

Assessment of Incidence of Distress and Utilization of Supportive Care Services in Multiple Myeloma Patients, a Retrospective Single Center Experience

Primary Endpoint Analysis from a Response Adaptive Phase II Clinical Trial of Carfilzomib, Lenalidomide, Dexamethasone Plus Daratumumab (KRd-Dara) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Implementing a Structured Health Care Transition (HCT) Process for Sickle Cell Disease Using Quality Improvement: Results from the Sickle Cell Trevor Thompson Transition Project HCT Learning Collaborative

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients

Efficacy of Subsequent Therapies in Multiple Myeloma Patients after Progression on a BCMA Targeting Therapy: A Single-Center Experience

Phase II Trial of In Vivo Purging with Daratumumab in Newly Diagnosed Multiple Myeloma

Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Patient Reported Financial Toxicity in Myeloproliferative Neoplasms

Patient Reported Financial Toxicity in Acute Leukemia

Ex Vivo Assessment of Tnb-383B, a Bcma-Bispecific Antibody, Against Primary Tumor and Endogenous T Cells from Relapsing Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only